Contents 1 min reading
Claim and source comparison
Phenibut: poison center reports, withdrawal cases, US supplement status and the origin of the half-life estimate.
· Bounded source comparison; not a complete clinical review or independent medical endorsement.
Human observational study
US poison centers recorded 1320 phenibut exposures in 2009–2019. These reports included 80 cases of coma and 3 deaths.
Exposures were not laboratory confirmed, and some cases involved other substances. These reports cannot estimate the risk for all users.
Source 5 · Full text read
Human case report / case review
Hardman et al. (2019) identified 22 withdrawal cases in the literature. Severe psychomotor agitation was reported in many cases.
Case reports cannot establish when tolerance begins, how long withdrawal lasts or an at-home discontinuation plan. A health professional should assess discontinuation after regular use.
Source 3 · Full text read
Regulatory scientific assessment
The FDA states that phenibut does not meet the US statutory definition of a dietary ingredient.
This determination concerns supplement labeling in the US. It does not establish product status in other countries or clinical effects.
Source 6 · Official summary read
Regulatory scientific assessment
A report prepared for the WHO expert committee notes that the Lapin review gives no primary citation for the reported 5.3-hour half-life.
This figure is insufficient to calculate individual elimination, duration of effects or repeat dosing.
Source 8 · Full text read
Correction · 2026-11-11: The untraceable half-life estimate and fixed withdrawal duration were removed. Limits of case reports and poison center data were clarified.
⚠ High Risk of Addiction
Phenibut carries risks of physical dependence, severe withdrawal, sedation, respiratory depression and loss of consciousness. Once- or twice-weekly use or a fixed maximum dose does not guarantee safety; no validated safe self-use protocol exists. After regular use, stopping should be planned with a clinician. Breathing difficulty, unconsciousness or severe agitation requires emergency care.
What is Phenibut?
Phenibut is a GABA-B receptor agonist. Zvejniece et al. (2015) also studied binding to the α2-δ subunit of voltage-dependent calcium channels in experimental models. A mechanism or an animal pain measure does not establish safe anxiety treatment in humans.
Mechanism of Effect
Clinical Trials
High-quality modern controlled human evidence for phenibut in anxiety and sleep is limited. The US FDA does not recognize phenibut as a dietary supplement ingredient. CDC poison-center data report serious toxicity, coma and deaths; these observational data do not quantify risk across all users.
Tolerance and Addiction
Case reports cannot establish when tolerance begins, how long withdrawal lasts or an at-home discontinuation plan. A health professional should assess discontinuation after regular use.
Related research and reading
These links show explicit editorial topic connections; they do not confirm a mechanism, efficacy or the safety of combined use. News dates refer to the source or event.
Educational guides
- Nootropic Cycling: Evidence and Limits
Tolerance, dependence and withdrawal are different phenomena. Breaks may be considered for some substances, but there is no validated cycling schedule for all nootropics.
Sources
- Lapin I. (2001). Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug. CNS Drug Reviews, 7(4), 471–481. PubMed · PMID 11830761
- Owen DR, et al. (2016). Phenibut (4-amino-3-phenyl-butyric acid): Availability, prevalence of use, desired effects and acute toxicity. Drug and Alcohol Review, 35(5), 591–596. PubMed · PMID 26693960
- Hardman MI, et al. (2019). Phenibut withdrawal: a comprehensive literature review and illustrative case report. Bosnian Journal of Basic Medical Sciences. PubMed · PMID 30501608
- Samokhvalov AV, et al. (2013). Phenibut dependence. BMJ Case Reports. PubMed · PMID 23391959
- Graves JM, et al. (2020). Notes from the Field: Phenibut Exposures Reported to Poison Centers — United States, 2009–2019. MMWR, 69(35), 1227–1228. https://www.cdc.gov/mmwr/volumes/69/wr/mm6935a5.htm PubMed · PMID 32881852
- US Food and Drug Administration. Phenibut in Dietary Supplements. https://www.fda.gov/food/information-select-dietary-supplement-ingredients-and-other-substances/phenibut-dietary-supplements US Food and Drug Administration
- Zvejniece L, et al. (2015). R-phenibut binds to the α2-δ subunit of voltage-dependent calcium channels and exerts gabapentin-like anti-nociceptive effects. Pharmacology Biochemistry and Behavior, 137, 23–29. doi:10.1016/j.pbb.2015.07.014. PubMed · PMID 26234470
- World Health Organization Expert Committee on Drug Dependence. (2021). Phenibut: Critical Review Report (advance copy), section 4B. https://cdn.who.int/media/docs/default-source/essential-medicines/unedited--advance-copy-44th-ecdd-critical-review-report_phenibut.pdf World Health Organization · Expert Committee on Drug Dependence
Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory
Frequently Asked Questions
High-quality modern controlled human evidence for phenibut in anxiety and sleep is limited. The US FDA does not recognize phenibut as a dietary supplement ingredient. CDC poison-center data report serious toxicity, coma and deaths; these observational data do not quantify risk across all users.
Phenibut carries risks of physical dependence, severe withdrawal, sedation, respiratory depression and loss of consciousness. Once- or twice-weekly use or a fixed maximum dose does not guarantee safety; no validated safe self-use protocol exists. After regular use, stopping should be planned with a clinician. Breathing difficulty, unconsciousness or severe agitation requires emergency care.
Sale and import status in Türkiye must be checked for the specific product. Verify supplement approval in the Ministry of Agriculture and Forestry GGBS list, and medicine authorization and conditions of use in TİTCK records. Online availability does not establish approval or unrestricted personal import; current Ministry of Trade conditions apply to postal and express shipments.
Case reports cannot establish when tolerance begins, how long withdrawal lasts or an at-home discontinuation plan. A health professional should assess discontinuation after regular use.